Celcuity Presents Updated VIKTORIA-1 Cohort Results at ESMO

In patients without liver metastases, median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the doublet, versus 9.1 months with alpelisib plus fulvestrant. ORR and median response duration were 59% and 19.4 months for the triplet, and 43% and 27.8 months for the doublet.